Dutch Court Bans Merck's Injectable Version of Keytruda in Certain European Markets
A Dutch court has ruled that Merck (MRK) cannot market an injectable version of its cancer drug Keytruda in certain European markets due to a patent dispute with Halozyme. The decision comes amid ongoing legal battles over the formulation and delivery method for Keytruda, which is one of Merck's top-selling drugs. The ruling has led to a decline in premarket trading for Merck shares as investors react to potential revenue implications from restricted access to this version of the drug across parts of Europe. The dispute centers on Halozyme’s Enhanze delivery technology used by Merck, which is at the heart of the patent infringement allegations. The outcome could affect how Keytruda is administered in certain European countries and may influence future licensing or settlement negotiations between the two companies.
